Stanford Cancer Institute
Stanford Cancer Institute is Stanford Medicine's NCI-designated Comprehensive Cancer Center, running 250+ cancer clinical trials across cell biology, imaging, immunotherapy, and early detection for patients and referring providers.
- Company typePrivate
- Founded1891
- HeadquartersStanford, United States
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingServices
What Stanford Cancer Institute does
Stanford Cancer Institute is the National Cancer Institute-designated Comprehensive Cancer Center embedded within Stanford Medicine at Stanford University. It serves cancer patients, referring physicians, and the broader research community through a portfolio of more than 250 actively recruiting clinical trials spanning diagnostic, prevention, and treatment strategies. The institute organizes its research around three core programs: Cancer Cell Biology, Cancer Imaging and Early Detection, and Cancer Immunotherapy, and is expanding into an early detection and interception vertical under newly appointed associate director Pamela Munster.
The institute's technology base combines structural biology (notably cryo-electron microscopy that produced an electrostatic two-step model of mTOR substrate selectivity), cell engineering for solid-tumor CAR-T therapies, and engineered recombinant cytokines aimed at reducing immunotherapy toxicity. Its research enterprise is operationally powered by a Clinical Trials Office of more than 200 staff that runs patient enrollment, protocol compliance, and contracts; a redesign of pre-screening to evaluate all referred patients drove clinic volume growth above 200% and new patient visits up approximately 150% over a few years.
As a nonprofit academic center, SCI does not sell a product in the commercial sense. Revenue is generated through a combination of clinical care delivered via Stanford Health Care, federal and private research grants (including NCI core grants tied to its Comprehensive Cancer Center status), and industry-funded clinical trials. Marketing and patient access run through the Stanford Medicine website, a public clinical trial search portal, social channels, events such as the Breakthroughs in Cancer speaker series and Comprehensive Cancer Research Training Program, physician referral networks, and earned media. In 2025 the institute launched the Weill Cancer Hub West, a $200M, ten-year partnership with UCSF Helen Diller Family Comprehensive Cancer Center targeting precision nutrition, AI-driven personalized treatment, cellular therapies, and immune cell engineering.
Stanford Cancer Institute firmographics
Firmographics- Name
- Stanford Cancer Institute
- Legal name
- Stanford Cancer Institute
- Website
- https://cancer.stanford.edu
- Company type
- Private
- Founded year
- 1891
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Stanford Cancer Institute is Stanford Medicine's NCI-designated Comprehensive Cancer Center, running 250+ cancer clinical trials across cell biology, imaging, immunotherapy, and early detection for patients and referring providers.
- Ownership category
- akta.pro rank
Stanford Cancer Institute industry classification
Industry- Product category
- Academic Cancer Center / Cancer Research and Clinical Trial Services
- NAICS
- Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)
- SIC
- Services-Hospitals (8060)
- akta.pro primary industry
- Oncology & Cancer Specialty Hospitals (HLAFAHAC)
- akta.pro secondary industries
- Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)
Keywords
Where Stanford Cancer Institute is headquartered
LocationHeadquarters
- HQ city
- Stanford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Stanford Cancer Institute business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Clinical Research and Patient Care Services: As an academic cancer center within Stanford Medicine, the institute generates revenue through clinical care services, government and private research grants, and clinical trial funding from pharmaceutical partners and federal agencies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Stanford Cancer Institute product offering
Product offeringCore offering
Stanford Cancer Institute is an NCI-designated Comprehensive Cancer Center that conducts translational cancer research and provides patient care through more than 250 actively recruiting clinical trials. It operates three core research programs—Cancer Cell Biology, Cancer Imaging and Early Detection, and Cancer Immunotherapy—and delivers cancer diagnosis, prevention, and treatment services at its Stanford, California campus in partnership with Stanford Health Care.
Product overview
Stanford Cancer Institute is a National Cancer Institute-designated Comprehensive Cancer Center offering a portfolio of cancer clinical trials and research programs. The institute operates over 250 actively recruiting clinical trials and manages three primary research programs: Cancer Cell Biology, Cancer Imaging and Early Detection, and Cancer Immunotherapy. The institute also participates in the Weill Cancer Hub West, a collaborative initiative with UCSF supporting advanced cancer research areas including AI-driven personalized treatment, cellular therapies, and radiopharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- Cancer Clinical Trials Investigational diagnostic, prevention, and treatment clinical trials for cancer patients, with over 250 trials actively recruiting, including adult, pediatric, and healthy-volunteer studies. Designed for cancer patients seeking access to cutting-edge experimental therapies and for referring physicians and trial sponsors seeking investigative sites.
- Cancer Cell Biology Research Program Research program investigating the molecules, mechanisms, and pathways involved in cancer pathogenesis, including structural biology and stem cell studies underlying cancer initiation and progression. Targets researchers, scientific collaborators, and translational programs developing new cancer therapeutics.
- Cancer Imaging and Early Detection Research Program Research program advancing cancer research, early detection, management, and outcomes through novel anatomical and molecular imaging strategies, including early-phase imaging-based diagnostic and interception research led by the associate director for early detection and interception.
- Cancer Immunotherapy Research Program Research program linking basic science and clinical translational strengths in cancer immunotherapy, including work on CAR-T cell therapy for solid tumors and engineered recombinant cytokines designed to reduce toxicity while improving patient outcomes.
Quantifiable outcome
- Clinic volume growth exceeding 200%
- +2 more outcomes
Companies that use Stanford Cancer Institute
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
Stanford Cancer Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Stanford Cancer Institute partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- UCSF Helen Diller Family Comprehensive Cancer CenterflagshipThe Weill Cancer Hub West is a $200 million initiative partnership between Stanford Cancer Institute and UCSF Helen Diller Family Comprehensive Cancer Center. The two institutions committed to raise $50 million each in matching gifts over 10 years. The hub supports multidisciplinary research projects including precision nutrition, AI-driven personalized cancer treatment, cellular therapies for solid tumors, and in-body immune cell engineering. The initiative launched in 2025 with over $25 million already in place, focusing on pilot projects in MYC-driven cancers, colorectal cancer immunotherapy, and next-generation radiopharmaceuticals.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Stanford Cancer Institute competitors and assessment
Company assessmentDirect peers
- Dana-Farber Cancer Institute: Harvard-affiliated NCI-designated Comprehensive Cancer Center with comparable depth in immunotherapy, early-phase trials, and translational research. Competes directly with Stanford for federal funding, top researchers, and pharma trial partnerships.
- Memorial Sloan Kettering Cancer Center: The leading NCI-designated Comprehensive Cancer Center on the East Coast, with comparable scale of clinical trials, research programs, and translational pipeline. MSKCC is the closest analog in terms of prestige, research output, and patient volume.
- Mayo Clinic Comprehensive Cancer Center: Multi-site NCI-designated Comprehensive Cancer Center with comparable breadth across oncology subspecialties. Competitor for patient referrals, clinical trial enrollment, and precision oncology partnerships.
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: Johns Hopkins-affiliated NCI-designated Comprehensive Cancer Center with comparable research depth across oncology subspecialties and a similarly university-affiliated operating model. Competes for top-tier talent and federal grant dollars.
- UCSF Helen Diller Family Comprehensive Cancer Center: UCSF's NCI-designated Comprehensive Cancer Center is Stanford's flagship strategic partner via the Weill Cancer Hub West, with directly comparable mission, structure, and patient population in Northern California. The two centers operate overlapping oncology research and clinical trial programs.
- Fred Hutchinson Cancer Center: Seattle-based NCI-designated Comprehensive Cancer Center with strong overlap in immunotherapy, cell therapy, and translational research. Direct competitor for NIH funding and biotech/pharma clinical trial collaborations.
- MD Anderson Cancer Center: The largest NCI-designated Comprehensive Cancer Center in the US, with comparable translational research programs, clinical trial volume, and oncology subspecialty depth. Direct competitor for talent, federal grants, and pharma-sponsored trials.
Others
- Weill Cornell Medicine / Meyer Cancer Center: Related to Stanford through the Weill family's philanthropic network, Weill Cornell has a parallel cancer center mission and overlapping funding sources. While not a direct geographic competitor, it represents a peer institution within the broader Weill-funded cancer research ecosystem.
Regional players
- UCLA Jonsson Comprehensive Cancer Center: Another California-based NCI-designated Comprehensive Cancer Center with overlapping research strengths in immunotherapy and translational science. Direct regional competitor for California patient referrals and biotech partnerships.
Broad incumbents
- Koch Institute for Integrative Cancer Research at MIT: MIT-based cancer research institute with comparable translational science and engineering-driven oncology focus, particularly in nanotechnology and immunoengineering. Overlaps with Stanford in cancer imaging and bioengineering approaches.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Stanford Cancer Institute social profiles
Digital presenceStanford Cancer Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stanford Cancer Institute leadership team
Management profileNumber of profiles
Profiles5 records
Stanford Cancer Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stanford Cancer Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stanford Cancer Institute
What does Stanford Cancer Institute do?
Stanford Cancer Institute is an NCI-designated Comprehensive Cancer Center that conducts translational cancer research and provides patient care through more than 250 actively recruiting clinical trials. It operates three core research programs—Cancer Cell Biology, Cancer Imaging and Early Detection, and Cancer Immunotherapy—and delivers cancer diagnosis, prevention, and treatment services at its Stanford, California campus in partnership with Stanford Health Care.
Is Stanford Cancer Institute a public or private company?
Stanford Cancer Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Stanford Cancer Institute founded?
Stanford Cancer Institute was founded in 1891. It employs 5,001 to 10,000 people.
Where is Stanford Cancer Institute based?
Stanford Cancer Institute is headquartered in Stanford, United States, in the North America region.
How does Stanford Cancer Institute make money?
One revenue line is on record: clinical Research and Patient Care Services.
Who are Stanford Cancer Institute's main competitors?
Direct peers on record are Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Mayo Clinic Comprehensive Cancer Center, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, Fred Hutchinson Cancer Center and MD Anderson Cancer Center. Weill Cornell Medicine / Meyer Cancer Center is listed as an others. UCLA Jonsson Comprehensive Cancer Center is listed as a regional player. Koch Institute for Integrative Cancer Research at MIT is listed as a broad incumbent.
Does Stanford Cancer Institute have an API?
No public API is recorded for Stanford Cancer Institute.
What industry is Stanford Cancer Institute in?
Stanford Cancer Institute's product category is Academic Cancer Center / Cancer Research and Clinical Trial Services. Its primary akta.pro industry code is HLAFAHAC, Oncology & Cancer Specialty Hospitals, with a secondary code of HLAFAAAM, Hospital-Integrated Cancer Centers (Acute Oncology Programs). Its NAICS code is 622310 and its SIC code is 8060.